Mr. Rene Goehrum reports

BIOSYENT ANNOUNCES EXTENSION OF REPAGYN AND PROKTIS-M AGREEMENT

BioSyent Inc.'s wholly owned subsidiary, BioSyent Pharma Inc., has extended its exclusive licence and distribution agreement with its European partner for the RepaGyn and Proktis-M products, extending BioSyent Pharma's exclusive Canadian rights to these products until 2032.

"RepaGyn and Proktis-M have been part of our product portfolio since we first launched these products in Canada in 2014," commented Rene Goehrum, president and chief executive officer of BioSyent. "We are pleased to continue to offer these trusted products to Canadian patients over the long term, and we look forward to their continued growth."

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other health care products that have been developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals who treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the company has 11,609,573 common shares outstanding.

We seek Safe Harbor.